EN DE
Watch D&D PharmaTech Co. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

D&D PharmaTech Co. (347850) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of D&D PharmaTech Co. stock KRW 18,900, price KRW 40,350, that is 53.2% below the price, quality 34 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

DD D&D PharmaTech Co. logo Thin data Nov 10, 2026

D&D PharmaTech Co.

347850 · KQ
Very expensive, weak quality

Our calculation puts a fair price 53% below what the stock costs today.

Low debt
Expensive Growth (revenue 3y +91.6 %/yr in KRW)
Revenue last quarter 28% below a year ago.
Fair value 18,900 KRW · Strongly overvalued
Quality 34/100
Negative free cash flow
Trails peers (2/7)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch D&D PharmaTech Co. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

111,200 KRW 6,425 KRW Fair Value 18,900 KRW May 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

30‑month range 6,425 KRW – 111,200 KRW · fair‑value band 14,175 KRW – 23,625 KRW · the 40,350 KRW price screens above the 18,900 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow D&D PharmaTech Co. in your weekly email

Every Wednesday you see whether D&D PharmaTech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea.

Show moreShow less

It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases.

The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications.

In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. The company was founded in 2014 and is based in Seongnam-si, South Korea.

Stock analysis

D&D PharmaTech Co. (347850) currently trades at 40,350 KRW, while our estimate is 18,900 KRW, 53% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 14,175 KRW (bear) to 23,625 KRW (bull), the price of 40,350 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

D&D PharmaTech Co. reported revenue of 4.3B KRW in FY2025 versus 1.4B KRW in FY2021, a compound +33.2%/yr. Reported net income was −23.6B KRW in FY2025.

Key figures

Market cap 1.8T KRW (≈ $1.3B) Small · EPS (TTM) −471.33 KRW · Return on equity −20.5% · Return on assets (EBIT) −62.5% (5-year average) · Operating margin −1,492% · Revenue (TTM) 2.8B KRW · Revenue growth (YoY) −28.4% · Free cash flow −21.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 64% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −53%, 347850 screens richer than that median.

Fair Value

Bear 14,175 KRW Fair Value 18,900 KRW Bull 23,625 KRW
Price 40,350 KRW · Downside -53.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 64
Does it invest with discipline instead of growing at any price?
Low Volatility 3
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−62.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+91.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,547.7% (2021) → −791.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

347850 screens overvalued: fair value 53% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare D&D PharmaTech Co. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −53.2% · Bottom 25%
Profitability
Return on assets −24.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) −28.4% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 22.10× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 347850
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 347850
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 347850
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 347850
argenx SE ARGX $971.55 $908.40 −7% vs 347850
CSL Limited CSL A$201.68 A$181.40 −10% vs 347850
Moderna, Inc MRNA $250.83 $158.70 −37% vs 347850
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 347850
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 347850
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 347850

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

D&D PharmaTech Co.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "D&D PharmaTech Co. Fair Value". https://www.fairvalue-calculator.com/stock/347850

Frequently asked questions

Is D&D PharmaTech Co. (347850) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 18,900 KRW versus a price of 40,350 KRW, about 53% lower (overvalued).
What is the fair value of 347850?
Our estimate for D&D PharmaTech Co. is 18,900 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 40,350 KRW.
What is the quality score of 347850?
D&D PharmaTech Co. has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for D&D PharmaTech Co. (347850)?
Our calculated price target is the estimate of 18,900 KRW (as of Nov 10, 2026). Cautious scenario 14,175 KRW, optimistic scenario 23,625 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the D&D PharmaTech Co. stock forecast for 2026?
Our estimate puts fair value at 18,900 KRW, about 53% lower versus a price of 40,350 KRW (overvalued). Cautious scenario 14,175 KRW, optimistic scenario 23,625 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of D&D PharmaTech Co. (347850)?
D&D PharmaTech Co. reported trailing-twelve-month revenue of about 2.8B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of D&D PharmaTech Co. (347850)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For D&D PharmaTech Co. it is 18,900 KRW per share (as of Nov 10, 2026), against a price of 40,350 KRW.
Is D&D PharmaTech Co. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 347850 trades above its calculated fair value: price 40,350 KRW, fair value 18,900 KRW, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 347850?
No. The price is what the market pays today (40,350 KRW); the fair value is what the company's own numbers justify (18,900 KRW). For D&D PharmaTech Co. the two are 21,450 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is D&D PharmaTech Co. worth?
The market values D&D PharmaTech Co. at about 1.8T KRW (market capitalisation, as of Nov 10, 2026). Per share that is 40,350 KRW; our models calculate a fair value of 18,900 KRW per share.
What do the bullish and bearish scenarios say about 347850?
Our models span a range for D&D PharmaTech Co.: cautious scenario 14,175 KRW, base 18,900 KRW, optimistic 23,625 KRW per share (as of Nov 10, 2026, price 40,350 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of D&D PharmaTech Co. (347850)?
Balance-sheet figures for D&D PharmaTech Co. (as of Nov 10, 2026): return on equity −20.5%. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 347850 from its 52-week high?
D&D PharmaTech Co. trades at 40,350 KRW, about 64% below its 52-week high of 111,200 KRW and 14% above the low of 35,400 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 18,900 KRW is for.
Which stocks are comparable to D&D PharmaTech Co.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is D&D PharmaTech Co. stock attractive at the current price?
The data as of Nov 10, 2026: price 40,350 KRW, calculated fair value 18,900 KRW (−53%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. D&D PharmaTech Co. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of D&D PharmaTech Co. (347850)?
The closing price on Nov 10, 2026 was 40,350 KRW. Our estimate is 18,900 KRW, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with D&D PharmaTech Co. right now?
The price sits above even our optimistic bull case (23,625 KRW). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of D&D PharmaTech Co.

How large is the market capitalisation of D&D PharmaTech Co. (347850)?
The market capitalisation of D&D PharmaTech Co. is 1.8T KRW (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of D&D PharmaTech Co. (347850)?
Earnings per share at D&D PharmaTech Co. are −471.33 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of D&D PharmaTech Co. (347850)?
The return on equity (ROE) of D&D PharmaTech Co. is −20.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of D&D PharmaTech Co. (347850)?
On an EBIT basis the return on assets of D&D PharmaTech Co. is −62.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of D&D PharmaTech Co. (347850)?
The operating margin of D&D PharmaTech Co. is −1,492% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at D&D PharmaTech Co. (347850)?
Revenue at D&D PharmaTech Co. is growing −28.4% versus a year earlier (3y avg +91.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does D&D PharmaTech Co. (347850) generate?
The free cash flow of D&D PharmaTech Co. is −21.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch D&D PharmaTech Co. in the live analysis

One click puts D&D PharmaTech Co. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.